Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
Season 10, Episode 17, Feb 29, 07:25 PM
Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma, his anticipated use of the agent since its inclusion on UCSF’s formulary, and the debate around Epstein-Barr virus as a selection criteria for treatment eligibility.